Ampd1, encoding the skeletal muscle-specific isoform of adenosine monophosphate deaminase, plays a role in skeletal muscle metabolism. It may be involved in pathways related to energy regulation, as it catalyzes the conversion of AMP to IMP and NH3, potentially influencing cellular energy states. Understanding its function is important for fields such as sports genomics and disease research related to muscle function and metabolism [3,4].

In gene-related studies, Ampd1-deficient homozygous mice showed a less severe state of insulin resistance, improved glucose tolerance, and enhanced insulin clearance when fed a high-fat diet. This indicates that Ampd1 may be a key regulator in insulin-related metabolic pathways [1]. In addition, in Ampd1-deficient mice challenged with a high-fat diet, phosphorylation levels of AMPK, Akt, and p70 S6 kinase in skeletal muscle were higher compared to wild-type mice, suggesting that Ampd1 deficiency activates the AMPK/Akt/mTORC1/p70 S6 kinase axis in skeletal muscle, which may contribute to improving insulin resistance [2]. In another study, knockdown of Ampd1 in mouse skeletal muscle affected muscle function, slowing contraction and relaxation kinetics in EDL muscle but not SOL muscle, and also modulated the [AMP]/AMPK responses to fatiguing contractions in an intensity-dependent manner in EDL muscle [3].

In conclusion, Ampd1 is crucial for skeletal muscle metabolism and energy-related processes. Studies using Ampd1-deficient mouse models have revealed its significance in insulin resistance-related metabolic diseases. These findings provide insights into potential therapeutic targets for diseases such as type 2 diabetes and also have implications for understanding muscle function in the context of exercise and athletic performance [1,2,3].